HomeNews & storiesDapivirine ring gives back the power to women to be able to take full control of their prevention
HomeNews & storiesDapivirine ring gives back the power to women to be able to take full control of their prevention
Dapivirine ring gives back the power to women to be able to take full control of their prevention
Last updated on: 11 March 2024
The Dapivirine ring is the first discreet, women-controlled, long-acting HIV prevention product. Dr Lilian advocates for approval and availability of the ring in Kenya, Rwanda, Tanzania and Uganda through the Empowering – Prevention by Choice project. In this interview she tells about the importance of this game changer for young women in HIV prevention.
“Having choice for HIV prevention,is extremely important given the high rates of new HIV infections affecting adolescent girls and young women across Africa. This shows directly that there is something we’re not doing right, despite the incredible strides countries are making towards ending AIDS. One thing that I think that is missing out for me from experience as a young woman, but also experience working with young women. Currently, we do not have enough options where young women can pick from to make sure that they’re able to protect themselves from getting HIV.
The dapivirine vaginal ring is one of the newest WHO recommended HIV prevention options. However, it’s still not available in most African countries, and most countries affected by HIV. It comes in as a game changer, the first ever, women control discrete HIV prevention option that could give back the power to girls and women to be able to take full control of their prevention.
While the efficacy of dapivirine vaginal ring is comparably low as compared to other WHO approved HIV prevention options I think it is still very important to have this tool available. Because I don’t think efficacy alone should be used to determine whether communities can access a certain intervention or not. We could have a variety of highly effective methods. But if they do not respond to the needs of the girls and young women, the result will be them not taking up those services.
For countries that have not yet approved the dapivirine vaginal ring, more than ever we need now the political will to making sure that we are able to review and approve the ring, prepare systems in place to making sure that it’s accessible to the communities as soon as possible, but also making sure that we secure resources to getting it closer to the communities as soon as we can.”
Through the EmpoweRing project we advocate for accelerated approval and uptake of the Dapivirine vaginal ring as an HIV prevention tool for women and girls in Uganda, Kenya, Tanzania and Rwanda. The Dapivirine ring is the first discreet, women-controlled, long-acting HIV prevention product. The project will be implemented by International Community of Women living with HIV Eastern Africa (ICWEA) and partners using the Youth Advocates model. This model seeks to empower and build resilience among adolescent girls and young women in addressing HIV needs.
330 organisations call for EC pledge ahead of Global Fund board meeting
330 organisations call for EC pledge ahead of Global Fund board meeting
On November 21, donors fell short of the Global Fund’s USD 18 billion target - a disappointing outcome at a time when increased support for HIV, TB and malaria is urgently needed.
Now, 330 organisations worldwide are urging the European Commission to confirm a €800 million pledge ahead of the February 2026 Board Meeting. This would help ensure timely funding for country programmes and unlock €400 million in US matching funds.
The Nov. 21 outcome fell short, but a stronger result is still possible - and the European Commission and EU Member States can play a key role, in line with Europe’s leadership in global health.
Identification of children for HIV treatment: Call for proposals 2026-2028
Identification of children for HIV treatment: Call for proposals 2026-2028
This open call for proposals invites community-based partners, medical institutions and non-governmental organisations (NGOs) to implement effective evidence-based approaches and interventions to reach new children and adolescents living with HIV (0-14) through testing and linking to anti-retroviral treatment and care in Malawi, Mozambique, South Africa, Tanzania and Nigeria.